Bone mineral density in schizophrenia an update of current meta-analysis and literature review under guideline of PRISMA

Medicine (United States)

Volumn 94, Issue 47, 2015, Pages e1967-

  Tseng, Ping Tao ^a   Chen, Yen Wen ^b   Yeh, Pin Yang ^a,c   Tu, Kun Yu ^a   Cheng, Yu Shian ^a   Wu, Ching Kuan ^a  

^a Tsyr Huey (Loving) Mental Hospital   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; META ANALYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; AGED; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; PRACTICE GUIDELINE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BONE DENSITY; FEMALE; GUIDELINES AS TOPIC; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; SCHIZOPHRENIA;

EID: 84988642704     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001967     Document Type: Article

References (56)

1. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4:368-381.
2. Kishimoto T, De Hert M, Carlson HE, et al. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012;25:415-429.
3. Halbreich U. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs. 2007;21:641-657.
4. O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonad-ism and osteoporosis in the treatment of schizophrenia. J Psycho-pharmacol. 2008;22(2 Suppl):70-75.
5. Stubbs B, Gaughran F, Mitchell AJ, et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry. 2015;37:126-133.
6. Kolanowski A, Fick D, Waller JL, Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20:217-225.
7. Bilici M, Cakirbay H, Guler M, et al. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophre-nia. Int J Neurosci. 2002;112:817-828.
8. Jung DU, Kelly DL, Oh MK, et al. Bone mineral density and osteoporosis risk in older patients with schizophrenia. J Clin Psychopharmacol. 2011;31:406-410.
9. Renn JH, Yang NP, Chueh CM, et al. Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord. 2009;10:1.
10. van der Leeuw C, Habets P, Domen P, et al. Bone mineral density as a marker of cumulative endogenous estrogen exposure: relationship to background genetic risk of psychotic disorder. Schizophr Res. 2013;143:25-31.
11. Sugawara N, Yasui-Furukori N, Umeda T, et al. Effect of age and disease on bone mass in Japanese patients with schizophrenia. Ann Gen Psychiatry. 2012;11:5.
12. Kishimoto T, Watanabe K, Takeuchi H, et al. Bone mineral density measurement in female inpatients with schizophrenia. Schizophr Res. 2005;77:113-115.
13. Maric N, Popovic V, Jasovic-Gasic M, et al. Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis. Schizophr Res. 2005;73:351-355.
14. Kishimoto T, Watanabe K, Shimada N, et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69:385-391.
15. Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroen-docrinology. 2011;94:246-254.
16. Wang MX, Hou RH, Jian J, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol Clin Exp. 2014;29:183-189.
17. Jung DU, Conley RR, Kelly DL, et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67:1391-1396.
18. Rey-Sanchez P, Lavado-Garcia JM, Canal-Macias ML, et al. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol. 2009;24:49-54.
19. Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinae-mia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem. 2010;47:292-300.
20. Lin CH, Huang KH, Chang YC, et al. Clozapine protects bone mineral density in female patients with schizophrenia. Int J Neuropsychopharmacol. 2012;15:897-906.
21. O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol. 2005;25:26-31.
22. Becker D, Liver O, Mester R, et al. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry. 2003;64:761-766.
23. Lin C, Lin C, Huang T, et al. Sex-specific factors for bone density in patients with schizophrenia. Int Clin Psychopharmacol. 2014;30:96-102.
24. Takahashi T, Uchida H, John M, et al. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort. Schizophr Res. 2013;147:383-386.
25. Lee TY, Chung MY, Chung HK, et al. Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study. Psychiatry Investig. 2010;7:278-284.
26. Meaney AM, O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res. 2007;93:136-143.
27. Oderda LH, Young JR, Asche CV, Pepper GA. Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann Pharmacother. 2012;46:917-928.
28. Crews MP, Howes OD. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol. 2012;27:15-23.
29. Stubbs B, De Hert M, Sepehry AA, et al. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand. 2014;130:470-486.
30. Kato Y, Ishikawa-Takata K, Yasaku K, et al. Changes in metacarpal bone mineral density with age and menopause using computed X-ray densitometry in Japanese women: cross-sectional and longitudinal study. Ann Hum Biol. 2005;32:760-772.
31. Riggs BL, Melton LJ, Robb RA, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res. 2008;23:205-214.
32. Chen H, Kubo KY. Bone three-dimensional microstructural features of the common osteoporotic fracture sites. World J Orthop. 2014;5:486-495.
33. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
34. Lehman D, Meyer JM. Decreased bone mineral density in male schizophrenia patients. Schizophr Res. 2005;76:131-133.
35. Bishop JR, Alexander B, Lund BC, Klepser TB. Osteoporosis screening and treatment in women with schizophrenia: a controlled study. Pharmacotherapy. 2004;24:515-521.
36. Abraham G, Paing WW, Kaminski J, et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry. 2003;160:1618-1620.
37. Howes OD, Wheeler MJ, Meaney AM, et al. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J Clin Psychopharmacol. 2005;25:259-261.
38. Sugawara N, Yasui-Furukori N, Fujii A, et al. No association between bone mass and prolactin levels among patients with schizophrenia. Hum Psychopharmacol. 2011;26:596-601.
39. Meaney AM, Smith S, Howes OD, et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004;184:503-508.
40. Do KQ, Trabesinger AH, Kirsten-Kruger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721-3728.
41. Mico JA, Rojas-Corrales MO, Gibert-Rahola J, et al. Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry. 2011;11:26.
42. Mancini A, Raimondo S, Di Segni C, et al. Comparison of plasma antioxidant levels in middle-aged and old male with idiopatic osteoporosis: preliminary data. Eur Rev Med Pharmacol Sci. 2014;18:2013-2019.
43. Rivas A, Romero A, Mariscal-Arcas M, et al. Association between dietary antioxidant quality score (DAQs) and bone mineral density in Spanish women. Nutricion Hospitalaria. 2012;27:1886-1893.
44. Sugawara N, Yasui-Furukori N, Sato Y, et al. Dietary patterns are associated with obesity in Japanese patients with schizophrenia. BMC Psychiatry. 2014;14:184.
45. Carter MI, Hinton PS. Physical activity and bone health. Mo Med. 2014;111:59-64.
46. Court-Brown CM, Caesar B. Epidemiology of adult fractures: a review. Injury. 2006;37:691-697.
47. Neuner JM, Laud PW, Schapira MM. A randomized study of the effect of 5-year and lifetime hip fracture risk information on physician recommendations for management of low bone density. J Clin Densitom. 2007;10:370-375.
48. Leder BZ, Tsai JN, Uihlein AV, et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteo-porosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99:1694-1700.
49. Chen H, Shoumura S, Emura S, Bunai Y. Regional variations of vertebral trabecular bone microstructure with age and gender. Osteoporos Int. 2008;19:1473-1483.
50. Dane C, Dane B, Cetin A, Erginbas M. The role of quantitative ultrasound in predicting osteoporosis defined by dual-energy X-ray absorptiometry in pre-and postmenopausal women. Climacteric. 2008;11:296-303.
51. Mulleman D, Legroux-Gerot I, Duquesnoy B, et al. Quantitative ultrasound of bone in male osteoporosis. Osteoporos Int. 2002;13:388-393.
52. Celi M, Rao C, Scialdoni A, et al. Bone mineral density evaluation in osteoporosis: why yes and why not? Aging Clin Exp Res. 2013;25(Suppl 1):S47-S49.
53. Partti K, Heliovaara M, Impivaara O, et al. Skeletal status in psychotic disorders: a population-based study. Psychosom Med. 2010;72:933-940.
54. Renn JH, Yang NP, Chou P. Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet Disord. 2010;11:35.
55. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry. 2007;190: 129-134.
56. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharma-col. 2007;21:768-773.